Business Trip
Business Trip explores the frontiers of the brain through conversations with founders, investors, and researchers at the intersection of neuroscience and technology.
Business Trip
Latest Episodes
Lux Capital’s Shahin Farshchi on Opportunities in Neuro
Shahin Farshchi, partner at Lux Capital, joins us to talk about investing in the next generation of neural interfaces. Lux is currently investing out of a $1.5B fund, and its portfolio includes Anduril, Hugging Face, Zoox, and CTRL-Labs.
Why Most Drugs Fail, and Why Virtual Tissue Models Beat Virtual Cell Models
Naren Tallapragada (co-founder of Tessel) joins to talk about the industry of modeling biology. While the field races to build virtual cell models, his team builds virtual tissue models, betting that predicting what an organ actually does matte...
.png)
Virtual Mitochondrial Models and the Case for Engineering Humans with Mariëlle van Kooten
Mariëlle van Kooten (CEO and co-founder of Powerhouse Biology) joins to make the case that mitochondria are the best place to start engineering the human body. Her team builds virtual mitochondria models to predict how a fix will behave before ...
Brain Organoids: from Space to AI with Alysson Muotri
Professor Alysson R. Muotri (geneticist and developmental biologist at UC San Diego) joins for a far out conversation about sending brain organoids to the International Space Station and what they're teaching us about aging, neurological diseas...
.png)
How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics
Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and what it takes to build these therapies the way large pharma would—culminating in...
